Webinar – Keeping Your Life Science Company in Compliance in China
December 16, 2011

Updating and Upgrading Your Regulatory and Anti-Corruption Compliance
In today’s aggressive compliance environment, it is crucial for life sciences companies to stay in full compliance with regulatory and anti-corruption requirements when developing and marketing their drugs, medical devices, and other products in China. In this 90-minute webcast, experts with hands-on experience will present the latest enforcement trends, case studies, and practical tips for compliance in China, focusing on these areas:
- Part I: Complying with recent changes in SFDA regulatory requirements
o Clinical trials
o Pre-market approval
o Sales and marketing
o Post-approval safety risk management - Part II: Complying with anti-corruption requirements in an aggressive enforcement environment
o Specific corruption challenges faced by life science companies in China
o FCPA and UK Bribery Act enforcement trends
o Compliance with local PRC anti-corruption laws and enforcement trends
o Practical tips for modifying compliance programs
Access this webinar by clicking on this link.

